Completed PHASE2 INTERVENTIONAL 2-arm NCT00116779

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles

Sponsor: Ferring Pharmaceuticals

Conditions Prostate Cancer

Interventions Degarelix

Updated 7 times since 2017 Last updated: Dec 15, 2011 Started: Feb 29, 2004 Primary completion: Aug 31, 2005 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Ferring Pharmaceuticals and has accumulated 7 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Pharmaceuticals

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Anchorage, United States , Aventura, United States , Barrie, Canada , Brantford, Canada , Burlington, Canada , Cheyenne, United States , Denver, United States , Fort Myers, United States , Fort Wayne, United States and 24 more locations